Table 1.

Studies on antihypertensive treatment in COVID-19.

Study	Compared Drugs/Study Drugs	Population	Results
Ip Andrew et al. medRxiv (2020) [51]	ACEI/ARBs	3017 patients with COVID-19, 1584 (52.5%) suffered from hypertension	Lower mortality in patients treated with ACEI (27%) or ARBs (23%) compared to other antihypertensive drugs (39%)
Liu Y., et al. medRxiv (2020) [53]	ACEI, ARB, CCB, BB, thiazide or none.	511 patients with COVID-19 and hypertension	Treatment with ARBs before hospitalization compared, reduced the risk of severe course of the disease COVID-19 (p = 0.025)
Zhang L., et al. medRxiv (2020) [55]	CCB	487 adult COVID-19 patients with hypertension, among these patients 44 received amlodipine	Inhibit the replication of SARS-CoV-2 in vitro. Amlodipine significantly reduced the death rate among COVID-19 patients. Case fatality rate decreased form 26,1% in non-amlodipine groups vs. 6,8% in amlodipine group
Xu J., et al. Frontiers of Medicine (2020) [47]	ACEI/ARBs	702 patients, 40 patients were receiving ACEI/ARB, 61 patients were taking medication other than ACEI/ARB	No statistically significant differences in in-hospital mortality (28% vs. 34%, p = 0.46), ICU admission (20% vs. 28%, p = 0.37) or invasive mechanical ventilation (18% vs. 26%, p = 0.31) between patients with or without ACEI/ARB. No association between chronic receipt of RAAS and severe outcomes of COVID-19.

Note: ACEI, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCB, calcium channel blockers; BB, beta-blockers.